VolitionRx publishes first peer-reviewed paper on Capture-Seq liquid biopsy technology
VNRX•Commercialization focus and partner discussions
Commercial focus targets multi-cancer early detection and minimal residual disease, with an estimated combined annual total addressable market of about $36 billion.
Technical evaluations are underway with potential licensing partners, signaling a push to accelerate commercialization via larger diagnostic companies.
Peer-reviewed paper details Capture-Seq results
VolitionRx published the first peer-reviewed paper detailing its Capture-Seq liquid biopsy approach for early cancer detection and minimal residual disease.
Results were already presented in the paper, with early clinical findings indicating strong cancer detection with no false positives in two cohorts.
Potential to improve liquid biopsy signal quality
The study suggests the method can isolate largely tumor-derived DNA from blood, potentially improving signal quality versus conventional liquid biopsy workflows.
